...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Balkan journal of medical genetics: BJMG >The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
【24h】

The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy

机译：土耳其非小细胞肺癌人群中EGFR和KRAS突变的频率及其对厄洛替尼治疗的反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this study, profiles of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma (KRAS) mutations and response to erlotinib therapy have been investigated in patients with non-small cell lung cancer (NSCLC). DNA from 300 patients with NSCLC was extracted from paraf-fin-embedded tissues. After the extracted DNA was sequenced by pyrosequencing method, a total of 97 (32.0%) patients out of 300 were detected to carry an EGFR mutation and 75 (25.0%) patients out of 300 carried a KRAS mutation; 20 (6.6%) patients were detected to carry both of EGFR and KRAS mutations. The EGFR mutations were found to be statistically significant in female patients (48.0 women vs. 28.0% men, non smokers (49.0 vs. 26.0%) and adenocarcinoma (37.8 vs. squamous 26.8%). The overall rate of survival in patients receiving erlotinib therapy than in patients who did not. In patients without the KRAS mutation, the median overall survival rate was 161 ?± 30 weeks with erlotinib therapy and 90 ?± 13 weeks in patients without erlotinib therapy. In patients having KRAS mutation, the median overall survival was 98 ?± 16 weeks with erlotinib therapy and 34 ?± 16 weeks with no erlotinib therapy. In our study, we once again demonstrated that the presence of these mutations affected response to erlotinib therapy. The KRAS mutations negatively affected survival rate with and without erlotinib therapy.
机译：在这项研究中，已经研究了非小细胞肺癌（NSCLC）患者的表皮生长因子受体（EGFR）和克尔斯滕ras肉瘤（KRAS）突变以及对厄洛替尼治疗的反应。从石蜡包埋的组织中提取300例NSCLC患者的DNA。通过焦磷酸测序法对提取的DNA进行测序后，检测到300名患者中有97名（32.0％）患者带有EGFR突变，300名患者中有75名（25.0％）患者具有KRAS突变;检测到20名（6.6％）患者同时携带EGFR和KRAS突变。发现EGFR突变在女性患者（48.0名女性对28.0％的男性，不吸烟者（49.0对26.0％）和腺癌（37.8对鳞状26.8％）中具有统计学显着性，接受厄洛替尼的患者的总生存率与未接受KRAS突变的患者相比，未接受KRAS突变的患者的中位总生存率为161±30周，未接受厄洛替尼治疗的患者的平均中位生存期为90±13周。厄洛替尼治疗的生存期为98±±16周，无厄洛替尼治疗的生存期为34±16周;在我们的研究中，我们再次证明了这些突变的存在会影响对厄洛替尼治疗的反应; KRAS突变对厄洛替尼治疗的生存率产生负面影响。无需厄洛替尼治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号